- NCIt
- C2896
Loading cancer entity…
Loading cancer entity…
Clinical trials
89 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07637734 | Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-3)(COVE-3) | recruiting | Phase 3 | 300 | Verrica Pharmaceuticals Inc.INDUSTRY | 2 | Sep 3, 2026 | clinicaltrials |
| NCT07457918 | Long-Term Follow-up Study of Cantharidin (YCANTH [VP-102/TO-208]) in Patients With Common Warts (Verruca Vulgaris)(COVE-4) | recruiting | Phase 3 | 600 | Verrica Pharmaceuticals Inc.INDUSTRY | 1 | May 5, 2026 |
| clinicaltrials |
| NCT05937672 | Cold Atmospheric Plasma Device Extension Study | terminated | Phase 3 | 60 | Medical University of South CarolinaOTHER | 1 | Apr 3, 2026 | clinicaltrials |
| NCT07246590 | Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-2)(COVE-2) | recruiting | Phase 3 | 300 | Verrica Pharmaceuticals Inc.INDUSTRY | 1 | Jan 21, 2026 | clinicaltrials |
| NCT05889845 | Candin for the Treatment of Common Warts | completed | Phase 3 | 330 | Nielsen BioSciences, Inc.INDUSTRY | 1 | Sep 5, 2025 | clinicaltrials |
| NCT07152041 | Newly-diagnosed Pediatric Ph-positive B-ALL Protocol(CAMS-Ph+ B-ALL) | recruiting | Phase 3 | 150 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 2 | Sep 3, 2025 | clinicaltrials |
| NCT03812510 | Safety Study of A-101 Topical Solution for the Treatment of Common Warts | completed | Phase 3 | 426 | Aclaris Therapeutics, Inc.INDUSTRY | 1 | Nov 23, 2020 | clinicaltrials |
| NCT03691831 | A Study of A-101 Topical Solution for the Treatment of Common Warts | completed | Phase 3 | 502 | Aclaris Therapeutics, Inc.INDUSTRY | 1 | Oct 27, 2020 | clinicaltrials |
| NCT03687372 | Study of A-101 Topical Solution for the Treatment of Common Warts | completed | Phase 3 | 503 | Aclaris Therapeutics, Inc.INDUSTRY | 1 | Oct 5, 2020 | clinicaltrials |
| NCT04288817 | Efficacy of Cryotherapy Combined With Intralesional Tuberculin PPD Versus Intralesional Tuberculin PPD in Treatment of Multiple Common Warts | unknown | Phase 3 | 40 | Assiut UniversityOTHER | 0 | Feb 28, 2020 | clinicaltrials |
| NCT02151630 | Pyruvic Acid Versus Salicylic Acid Preparation in Treatment of Plantar Warts | unknown | Phase 2 / Phase 3 | 60 | Isfahan University of Medical SciencesOTHER | 1 | May 30, 2014 | clinicaltrials |
Data updated 22 days agoSource updated Sep 3, 2026source: clinicaltrials